+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill



Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill



Diagnostic Microbiology & Infectious Disease 38(1): 37-41



Pseudomonal infections have a high rate of morbidity and mortality, thus combination therapy is often recommended. We compared the activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, or trovafloxacin at different concentrations against P. aeruginosa using time-kill methodology. MICs were determined for 4 clinical isolates of P. aeruginosa. Time-kill studies were conducted over 24 h. Each drug was tested alone and in combination using the following concentrations: 2 and 1/4, 1/4 and 2, and 1/4 and 1/4xMIC of piperacillin/tazobactam and amikacin, ciprofloxacin, or trovafloxacin. Combinations were classified as synergistic, indifferent, or antagonistic. Synergy was defined as > or = 2-log(10) decrease in CFU/mL at 24 h with the combination when compared to the most active single agent and the number of surviving organisms for the antimicrobial combination was > or =2-log(10) less than the initial inoculum. The MICs for piperacillin/tazobactam, amikacin, ciprofloxacin, and trovafloxacin, ranged from 4/4-512/4, 0.5-4, 0.125-4, and 0.5-8 microg/mL, respectively. Fifty eight percent of the combinations using concentrations of 1/4xMIC of piperacillin/tazobactam and 2xMIC of amikacin, ciprofloxacin, and trovafloxacin or 2xMIC of piperacillin/tazobactam and 1/4xMIC of amikacin, ciprofloxacin, and trovafloxacin were synergistic. Although no differences existed in synergistic activity between the two combinations, the 1/4 and 2xMIC maintained colony counts below the limit of quantification for 24 h for a significantly greater percentage of isolates than the 2 and 1/4xMIC combinations (75 and 25%, respectively; p = 0.04). Overall, synergy was most frequently (42%) noted with the piperacillin/tazobactam and amikacin combinations followed by 33 and 8% of the piperacillin/tazobactam and trovafloxacin and ciprofloxacin combinations. No combination demonstrated antagonism. Further more extensive studies are necessary to determine clinical significance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010123788

Download citation: RISBibTeXText

PMID: 11025182

DOI: 10.1016/s0732-8893(00)00162-0


Related references

Activity of piperacillin/tazobactam in combination with amikacin , trovafloxacin , and ciprofloxacin against Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 289, 1999

Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. ChemoTherapy 50(4): 202-210, 2004

Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes. Journal of Antimicrobial ChemoTherapy 39 Suppl B: 23-27, 1997

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 39(8): 1711-1716, 1995

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant Pseudomonas aeruginosa Strains. Chemotherapy 49(6): 294-297, 2003

In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. ChemoTherapy 49(6): 294-297, 2003

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagnostic Microbiology & Infectious Disease 44(1): 35-41, 2002

Synergistic activity of gentamicin, ciprofloxacin, and levofloxacin in combination with cefepime and piperacillin/tazobactam against P aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 170-171, 2001

Piperacillin/tazobactam or ceftazidime with amikacin or not against Viridans streptococci Serum inhibitory activity, bactericidal activity and time-kill bioactivity in healthy volunteers Synergy?. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 8, 1997

Comparative antibacterial activities of meropenem , imipenem , ceftazidime , piperacillin/tazobactam , ciprofloxacin and tobramycin , singly and in combination against resistant and susceptible isolates of Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 104, 1995

Comparison of the Bactericidal Activity of Trovafloxacin and Ciprofloxacin, Alone and in Combination with Cefepime, against Pseudomonas aeruginosa. Chemotherapy 46(6): 383-389, 2000

Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa. ChemoTherapy 46(6): 383-389, 2000

Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa. ChemoTherapy 50(1): 27-30, 2004

In vitro activity of tazobactam and piperacillin combination against 224 strains of Pseudomonas aeruginosa according to the production of beta-lactamase. Pathologie-Biologie 39(5): 361-366, 1991

Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrobial Agents and ChemoTherapy 40(3): 772-775, 1996